Advertisement

Topics

Biogen Release: New Data Reaffirm Clinically Meaningful Benefit Of SPINRAZA (Nusinersen) In Individuals With Spinal Muscular Atrophy Across Disease Severity

20:00 EDT 28 Jun 2017 | BioSpace

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) will...

Original Article: Biogen Release: New Data Reaffirm Clinically Meaningful Benefit Of SPINRAZA (Nusinersen) In Individuals With Spinal Muscular Atrophy Across Disease Severity

NEXT ARTICLE

More From BioPortfolio on "Biogen Release: New Data Reaffirm Clinically Meaningful Benefit Of SPINRAZA (Nusinersen) In Individuals With Spinal Muscular Atrophy Across Disease Severity"

Quick Search
Advertisement